Table 2.
Baseline characteristics of 14 eligible patients in prospective study.
| Patient number | Age (years) | Gender | Disease extent | Dose of prior mesalazine (mg) | Severity | Rachmilewitz CAI |
|---|---|---|---|---|---|---|
| 1 | 27 | M | Extensive | 3000 | Mild | 5 |
| 2 | 73 | F | Left-sided | 3000 | Mild | 6 |
| 3 | 37 | M | Left-sided | 2250 | Mild | 5 |
| 4 | 39 | F | Extensive | 3000 | Mild | 5 |
| 5 | 63 | F | Extensive | 2250 | Moderate | 10 |
| 6 | 33 | F | Left-sided | 2250 | Mild | 5 |
| 7 | 59 | F | Extensive | 3000 | Mild | 6 |
| 8 | 40 | M | Extensive | 2250 | Mild | 5 |
| 9 | 27 | M | Extensive | 2250 | Moderate | 8 |
| 10 | 57 | M | Left-sided | 2250 | Moderate | 7 |
| 11 | 27 | F | Proctitis | 2250 | Mild | 5 |
| 12 | 72 | M | Extensive | 2250 | Moderate | 8 |
| 13 | 31 | F | Proctitis | 2250 | Mild | 5 |
| 14 | 47 | M | Left-sided | 2250 | Mild | 5 |